Dr
Nienke
Lubben

Partner & Patent Attorney

York Office The Hague Office

Life sciences

Telephone. +44(0) 1904 732 120
Mobile. +44(0) 777 265 2294
Email. [email protected]

Experience

Nienke's portfolio encompasses a diverse range of biological subject matter including: cell therapy, biomarkers, biosimilars, antibodies, immunology, therapeutics, cell biology, biotechnology, enzymology, diagnostics and biopharmaceuticals. She handles all patent related matters including: preparing patent applications, prosecuting patent applications before the EPO and UKIPO, managing worldwide patent prosecution, strategic reviews, due diligence, and validity opinions.

Nienke has considerable experience working with universities and spin-out companies and can bring a depth of commercially relevant advice from her experience in working for a start-up biotech company prior to entering the profession. Nienke also works with SMEs and large multinational companies. Her pragmatic advice is appropriately tailored to her client's individual needs.

Nienke has represented clients before the Oppositions Division of the EPO and has a particular interest in opposition matters. Her ability to quickly assimilate and utilise scientific literature to the benefit of her clients is a key strength during oral proceedings before both the Opposition Division and the Boards of Appeal of the EPO.

Nienke qualified as a Patent Attorney in 2012 and was awarded the Strode Prize for obtaining the highest mark in the UK finals law exam, P2. She also holds a Post-Graduate Certificate in Intellectual Property Law from the Queen Mary, University of London, obtained with distinction. She obtained her PhD from the University of Cambridge in Infection and Immunity and graduated with a First Class Honours degree in Biological Sciences (Genetics) from the University of Leicester with the highest mark in her year.

Qualifications

Patent Attorney

Chartered (UK)
European


BSC

Biological Sciences (genetics)

PHD

Infection and Immunity

Recognition

MIP IP Rising Star 2019/20

MIP IP Rising Star 2018/19

Publications

MIP IP Rising Stars 2019/20

View publication online

Related News

Food technology companies and investors - the value of IP landscape analysis

Case study – alt fat innovation Many companies and investors are aware of the importance of identifying and protecting their innovations, and in particular of the importance of obtaining patents …

Read article
Event - 29th September 2022

North East Automotive Expo 2022

HGF will be exhibiting at The North East Automotive Alliance’s flagship Expo on 29th September 2022. The event is an industry highlight for companies operating within the region’s automotive supply …

Event details
Event - 21st-22nd September 2022

Medical Technology Ireland 2022

Medical Technology Ireland Conference 2022 will be held on 21-22 September at the Galway Racecource. Medical Technology Ireland is a new high-profile National and International event attracting global suppliers to …

Event details

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.